Mumbai, Maharashtra, India, July 2026 — Bliss GVS Pharma Ltd. has announced the appointment of Rahul Adakmol as its Chief Executive Officer (CEO). The appointment, approved by the company’s Board of Directors, reinforces Bliss GVS Pharma’s commitment to visionary leadership and its core values of Innovation, Integrity, Excellence, and Entrepreneurship.
Rahul Adakmol brings more than two decades of leadership experience across the pharmaceutical and healthcare industry, with expertise spanning sales, marketing, manufacturing, supply chain, medico-regulatory affairs, strategy, licensing, mergers and acquisitions, portfolio management, research and development, and international operations. As Chief Executive Officer, he will lead the company’s next phase of growth, leveraging his experience in business transformation, global expansion, and operational excellence.
Prior to joining Bliss GVS Pharma Ltd., Rahul served as Chief Operating Officer – International Operations at Bharat Serums and Vaccines Limited (BSV), where he played a pivotal role in transforming the international business following Advent International’s acquisition of the company. During his tenure, he successfully built a USD 100+ million branded specialty international business focused on IVF, women’s health, and critical care, delivering over 50% EBITDA and a 25% five-year CAGR. He also led portfolio prioritization, licensing, cross-border M&A initiatives, established commercial operations across 15 countries, and was a core member of the leadership team that supported Advent International’s successful exit at a valuation of approximately USD 1.6 billion before the company’s integration with Mankind Pharma.
Earlier, Rahul spent over 15 years at Dr. Reddy’s Laboratories, where he held several senior leadership positions across business development, portfolio management, corporate planning, and strategic alliances. As Vice President and Head – Business Development for Branded Markets (India & Emerging Markets), he led mergers and acquisitions, licensing, and strategic alliances for the company’s USD 800+ million branded business, successfully concluding landmark acquisitions including UCB Pharma’s India business and Wockhardt’s branded business, alongside more than 30 licensing agreements across India and emerging markets. He also led strategic alliances with global pharmaceutical companies including Amgen, UCB, and AstraZeneca, while receiving the prestigious Chairman’s Excellence Award for outstanding leadership and organizational impact. Earlier in his career, Rahul worked with Reliance Industries Limited, contributing to strategic projects at the Jamnagar refinery.
Rahul is an alumnus of the Indian Institute of Management Bangalore (IIM Bangalore), where he completed his management education between 2003 and 2005, complementing his strong foundation in business strategy and leadership.
About Bliss GVS Pharma Ltd.
Bliss GVS Pharma Ltd. is a fast-growing global pharmaceutical company focused on developing, manufacturing, and marketing high-quality pharmaceutical formulations at affordable prices across international markets.
The company is recognized as one of the world’s leading manufacturers of suppositories and pessaries, with one of the industry’s largest product portfolios in these dosage forms. Its manufacturing facilities are certified to international quality standards, including EU GMP, WHO GMP, OHSAS 18001, and ISO 14001, making Bliss GVS the only EU-GMP-certified suppositories manufacturer in India. The company also holds a strong leadership position in anti-malarial therapies across African markets while continuing to expand its research, manufacturing, and global commercial capabilities across more than 60 countries.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
